3 Month Outcome of Ziv-aflibercept for DME
NCT02772497 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2017-07-06
Summary
The purpose is to show the 3-month efficacy and safety in diabetic macular edema treated with intravitreal ziv-aflibercept.
Conditions
Interventions
- DRUG
-
Ziv aflibercept
Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
Sponsors & Collaborators
-
Marashi Eye Clinic
lead OTHER
Principal Investigators
-
Ameen Marashi, MD · Aleppo Syria
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-01-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
More Related Trials
-
Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser
NCT03590444 ·Status: COMPLETED ·Phase: PHASE4
-
Aflibercept Plus Micropulse Laser Versus Aflibercept Monotherapy for Diabetic Macular Edema
NCT04014556 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
NCT04288232 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
NCT06908876 ·Status: RECRUITING ·Phase: PHASE2
-
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema
NCT02441907 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection
NCT03297684 ·Status: UNKNOWN
-
Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection
NCT03453281 ·Status: COMPLETED ·Phase: PHASE4
-
Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)
NCT03780361 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
NCT06422507 ·Status: COMPLETED ·Phase: PHASE3
-
Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome
NCT05080803 ·Status: COMPLETED
-
Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema
NCT02924311 ·Status: COMPLETED
-
A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema
NCT05511038 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
NCT02559180 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema
NCT02850263 ·Status: COMPLETED
-
Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
NCT02788877 ·Status: UNKNOWN ·Phase: PHASE4
-
Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema
NCT07096713 ·Status: COMPLETED ·Phase: NA
-
Intravitreal Aflibercept Injection in Vision Impairment Due to DME
NCT01331681 ·Status: COMPLETED ·Phase: PHASE3
-
New Concepts in Diabetic Macular Edema (DME)
NCT04186702 ·Status: COMPLETED ·Phase: NA
-
Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
NCT04429503 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
NCT05324774 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy Analysis of Anti-VEGF Drugs Combined With Micropulse Laser in the Treatment of Diabetic Macular Edema
NCT05759884 ·Status: UNKNOWN ·Phase: NA
-
Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa
NCT02554747 ·Status: COMPLETED ·Phase: NA
-
Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
NCT06205979 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Treatment of Refractory Diabetic Macular Edema With Infliximab
NCT00505947 ·Status: TERMINATED ·Phase: PHASE3
-
Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography
NCT03783832 ·Status: UNKNOWN